Once we look like we will clear phase 2b investors will start running discounted cash flows for the DMD market and then you will see things take off but a few people have stated Phase 2a, no placebo and big U.S. money wants to see drug head to head vs placebo. Only about $4 mil in bank so 2b trial is not a done deal yet. Akki gets a hard time about negativity but these are things holding ANP back. Like it or not. I would also like to see data on cardio myopathy if enough subjects in 2b. Think 1102 has real possibility of helping myopathy patients too.
Once we look like we will clear phase 2b investors will start...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.001(1.25%) |
Mkt cap ! $83.73M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.2¢ | 7.9¢ | $153.8K | 1.914M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 927041 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 218878 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |